AR103093A1 - Péptidos macrocíclicos que inhiben interacciones proteína / proteína de proteína de la muerte (pd-1 / pd-l1) e inhiben interacción cd80 / pd-l1 - Google Patents
Péptidos macrocíclicos que inhiben interacciones proteína / proteína de proteína de la muerte (pd-1 / pd-l1) e inhiben interacción cd80 / pd-l1Info
- Publication number
- AR103093A1 AR103093A1 ARP150104168A ARP150104168A AR103093A1 AR 103093 A1 AR103093 A1 AR 103093A1 AR P150104168 A ARP150104168 A AR P150104168A AR P150104168 A ARP150104168 A AR P150104168A AR 103093 A1 AR103093 A1 AR 103093A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- halo
- independently selected
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Péptidos macrocíclicos que inhiben las interacciones proteína / proteína PPD-1 / PD-L1 y PD-L1 / CD80, y por ende, son útiles para la mejora de varias enfermedades, que incluyen el cáncer y las enfermedades infecciosas. Reivindicación 1: Un compuesto, caracterizado porque tiene la fórmula (1) o una sal de este aceptable desde el punto de vista farmacéutico, en donde: A se selecciona de un enlace del grupo de fórmulas (2), en donde: la línea ondulada * indica el punto de unión al grupo carbonilo y la línea ondulada indica el punto de unión al átomo de nitrógeno; z es 0, 1 ó 2; w es 1 ó 2; n es 0 ó 1; m es 1 ó 2; m es 0 ó 1; p es 0, 1 ó 2; Rˣ se selecciona de hidrógeno, amino, hidroxi y metilo; R¹⁴ y R¹⁵ se seleccionan independientemente de hidrógeno y metilo; y Rᶻ se selecciona de hidrógeno y -C(O)NHR¹⁶; en donde R¹⁶ se selecciona de hidrógeno, -CHR¹⁷C(O)NH₂, -CHR¹⁷C(O)NHCHR¹⁸C(O)NH₂ y -CHR¹⁷C(O)NHCHR¹⁸C(O)NHCH₂C(O)NH₂; en donde R¹⁷ se seleccione de hidrogeno y -CH₂OH, y en donde R¹⁸ se selecciona de hidrógeno y metilo; Rᵛ es hidrógeno o una cadena lateral de aminoácido natural; Rᶜ, Rᶠ, Rʰ, Rⁱ y Rᵐ son hidrogeno; Rⁿ es hidrógeno o metilo, o Rᵛ y Rⁿ forman un anillo de pirrolidina; Rᵃ es hidrógeno o metilo; Rʲ se selecciona de hidrógeno, C₁₋₆ alcoxi-C₁₋₆ alquilo, C₁₋₆ alquilo, carboxi-C₁₋₆ alquilo, halo-C₁₋₆ alquilo, hidroxi-C₁₋₆ alquilo, (NRᵃRᵇ)C₁₋₆ alquilo, en donde Rᵃ y Rᵇ se seleccionan independientemente de hidrógeno y C₁₋₆ alquilo; y fenil-C₁₋₆ alquilo, en donde fenilo se sustituye opcionalmente con 1, 2, 3, 4 ó 5 grupos seleccionados independientemente de C₁₋₆ alcoxi, C₁₋₆ alquilo, ciano, halo y nitro; R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² y R¹³ se seleccionan independientemente de una cadena lateral de aminoácido natural y una cadena lateral de aminoácido no natural; o R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² y R¹³ pueden formar, cada uno independientemente, un anillo con el grupo R próximo correspondiente como se describe más adelante; Rᵇ se selecciona de C₁₋₆ alcoxi-C₁₋₆ alquilo, C₁₋₆ alquilo, carboxi-C₁₋₆ alquilo, halo-C₁₋₆ alquilo, hidroxi-C₁₋₆ alquilo, (NRᵃRᵇ)C₁₋₆ alquilo, en donde Rᵃ y Rᵇ se seleccionan independientemente de hidrógeno y C₁₋₆ alquilo; y fenil-C₁₋₆ alquilo, en donde fenilo se sustituye opcionalmente con 1, 2, 3, 4 ó 5 grupos seleccionados independientemente de C₁₋₆ alcoxi, C₁₋₆ alquilo, ciano, halo y nitro; o Rᵇ y R², junto con los átomos a los que están unidos, forman un anillo seleccionado de azetidina, pirrolidina, morfolina, piperidina, piperazina y tetrahidrotiazol; en donde cada anillo se sustituye opcionalmente con 1 a 4 grupos seleccionados independientemente de amino, ciano, metilo, halo e hidroxi; Rᵈ se selecciona de hidrógeno, C₁₋₆ alcoxi-C₁₋₆ alquilo, C₁₋₆ alquilo, carboxi-C₁₋₆ alquilo, halo-C₁₋₆ alquilo, hidroxi-C₁₋₆ alquilo, (NRᵃRᵇ)C₁₋₆ alquilo, en donde Rᵃ y Rᵇ se seleccionan independientemente de hidrógeno y C₁₋₆ alquilo; y fenil-C₁₋₆ alquilo, en donde fenilo se sustituye opcionalmente con 1, 2, 3, 4 ó 5 grupos seleccionados independientemente de C₁₋₆ alcoxi, C₁₋₆ alquilo, ciano, halo y nitro; o Rᵈ y R⁴, junto con los átomos a los que están unidos, pueden formar un anillo seleccionado de azetidina, pirrolidina, morfolina, piperidina, piperazina y tetrahidrotiazol; en donde cada anillo se sustituye opcionalmente con 1 a 4 grupos seleccionados independientemente de amino, ciano, metilo, halo, hidroxi y fenilo; Rᵉ se selecciona de hidrógeno, C₁₋₆ alcoxi-C₁₋₆ alquilo, C₁₋₆ alquilo, carboxi-C₁₋₆ alquilo, halo-C₁₋₆ alquilo, hidroxi-C₁₋₆ alquilo, (NRᵃRᵇ)C₁₋₆ alquilo, en donde Rᵃ y Rᵇ se seleccionan independientemente de hidrógeno y C₁₋₆ alquilo; y fenil C₁₋₆ alquilo, en donde fenilo se sustituye opcionalmente con 1, 2, 3, 4 ó 5 grupos seleccionados independientemente de C₁₋₆ alcoxi, C₁₋₆ alquilo, ciano, halo y nitro; o Rᵉ y R⁵, junto con los átomos a los que están unidos, pueden formar un anillo seleccionado de azetidina, pirrolidina, morfolina, piperidina, piperazina y tetrahidrotiazol; en donde cada anillo se sustituye opcionalmente con 1 a 4 grupos seleccionados independientemente de amino, ciano, metilo, halo e hidroxi; Rᵍ se selecciona de hidrógeno, C₁₋₆ alcoxi-C₁₋₆ alquilo, C₁₋₆ alquilo, carboxi-C₁₋₆ alquilo, halo-C₁₋₆ alquilo, hidroxi-C₁₋₆ alquilo, (NRᵃRᵇ)C₁₋₆ alquilo, en donde Rᵃ y Rᵇ se seleccionan independientemente de hidrógeno y C₁₋₆ alquilo; y fenil-C₁₋₆ alquilo, en donde fenilo se sustituye opcionalmente con 1, 2, 3, 4 ó 5 grupos seleccionados independientemente de C₁₋₆ alcoxi, C₁₋₆ alquilo, ciano, halo y nitro; o Rᵍ y R⁷, junto con los átomos a los que están unidos, pueden formar un anillo seleccionado de azetidina, pirrolidina, morfolina, piperidina, piperazina y tetrahidrotiazol; en donde cada anillo se sustituye opcionalmente con 1 a 4 grupos seleccionados independientemente de amino, bencilo opcionalmente sustituido con un grupo halo, benciloxi, ciano, ciclohexilo, metilo, halo, hidroxi, isoquinoliniloxi opcionalmente sustituido con un grupo metoxi, quinolíniloxi sustituido opcionalmente con un grupo halo, y tetrazolilo; y en donde el anillo de pirrolidina y el anillo de piperidina se fusionan opcionalmente a un grupo ciclohexilo, fenilo o indol; siempre que al menos uno de Rᵃ, Rᵇ, Rᵈ, Rᵉ, Rᵍ, Rʲ, Rᵏ y Rˡ se seleccione de C₁₋₆ alcoxi-C₁₋₆ alquilo, C₂₋₆ alquilo, carboxi-C₁₋₆ alquilo, halo-C₁₋₆ alquilo, hidroxi-C₁₋₆ alquilo, (NRᵃRᵇ)C₁₋₆ alquilo, en donde Rᵃ y Rᵇ se seleccionan independientemente de hidrógeno y C₁₋₆ alquilo; y fenil-C₁₋₆ alquilo, en donde fenilo se sustituye opcionalmente con 1, 2, 3, 4 ó 5 grupos seleccionados independientemente de C₁₋₆ alcoxi, C₁₋₆ alquilo, ciano, halo y nitro.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462094008P | 2014-12-18 | 2014-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR103093A1 true AR103093A1 (es) | 2017-04-12 |
Family
ID=55071200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150104168A AR103093A1 (es) | 2014-12-18 | 2015-12-17 | Péptidos macrocíclicos que inhiben interacciones proteína / proteína de proteína de la muerte (pd-1 / pd-l1) e inhiben interacción cd80 / pd-l1 |
Country Status (16)
Country | Link |
---|---|
US (1) | US9861680B2 (es) |
EP (1) | EP3233888B1 (es) |
JP (1) | JP6625129B2 (es) |
KR (1) | KR102602643B1 (es) |
CN (1) | CN107108697B (es) |
AR (1) | AR103093A1 (es) |
AU (1) | AU2015362703A1 (es) |
BR (1) | BR112017012679A2 (es) |
CA (1) | CA2971189A1 (es) |
EA (1) | EA033894B1 (es) |
ES (1) | ES2940632T3 (es) |
IL (1) | IL252853A0 (es) |
MX (1) | MX2017007677A (es) |
SG (1) | SG11201704823TA (es) |
TW (1) | TW201629086A (es) |
WO (1) | WO2016100285A1 (es) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2893597C (en) | 2012-12-07 | 2021-06-29 | Chemocentryx, Inc. | Diazole lactams |
MX2017003201A (es) | 2014-09-11 | 2017-05-23 | Bristol Myers Squibb Co | Inhibidores macrociclicos de las interacciones proteina/proteina de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1. |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
RS62809B1 (sr) | 2015-05-21 | 2022-02-28 | Chemocentryx Inc | Modulatori ccr2 |
US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
US10358463B2 (en) * | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
AU2017246460B2 (en) | 2016-04-07 | 2021-04-22 | Chemocentryx, Inc. | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
SI3458111T1 (sl) | 2016-05-19 | 2021-07-30 | Bristol-Myers Squibb Company | Imunomodulatorji prikazani s pet |
EP3514167B1 (en) * | 2016-09-13 | 2022-04-13 | Daiichi Sankyo Company, Limited | Thrombospondin 1-binding peptide |
EP3526323B1 (en) | 2016-10-14 | 2023-03-29 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
CN110267971B (zh) * | 2016-11-07 | 2023-12-19 | 百时美施贵宝公司 | 免疫调节剂 |
EP3558395A4 (en) | 2016-12-23 | 2020-08-12 | The Johns Hopkins University | TUMOR AND IMMUNE CELL IMAGING ON THE BASIS OF PD-L1 EXPRESSION |
US11524979B2 (en) * | 2017-06-15 | 2022-12-13 | University Of Washington | Macrocyclic polypeptides |
KR20200020858A (ko) * | 2017-06-23 | 2020-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1의 길항제로서 작용하는 면역조정제 |
CN107602705B (zh) * | 2017-09-13 | 2018-08-31 | 北京鼎成肽源生物技术有限公司 | 一种基于蛋白互作用于检测细胞pd1表达情况的融合蛋白及其应用 |
JP7453139B2 (ja) | 2017-09-25 | 2024-03-19 | ケモセントリックス,インコーポレイティド | ケモカイン受容体2(ccr2)アンタゴニスト及びpd-1/pd-l1阻害剤を使用した併用療法 |
US11492375B2 (en) | 2017-10-03 | 2022-11-08 | Bristol-Myers Squibb Company | Cyclic peptide immunomodulators |
AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
EP3737367A4 (en) | 2018-01-08 | 2022-11-09 | ChemoCentryx, Inc. | METHODS OF TREATING SOLID TUMORS USING CCR2 ANTAGONISTS |
PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
EP3804758A4 (en) | 2018-05-31 | 2022-03-02 | ONO Pharmaceutical Co., Ltd. | BIOMARKER FOR ASSESSING THE EFFECTIVENESS OF AN IMMUNE CHECKPOINT INHIBITOR |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
US11130773B2 (en) | 2018-10-11 | 2021-09-28 | Ono Pharmaceutical Co., Ltd. | STING agonistic compound |
WO2020092621A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
WO2020198672A1 (en) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
EP3946628A1 (en) | 2019-03-28 | 2022-02-09 | Bristol-Myers Squibb Company | Methods of treating tumor |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
EP3972694A1 (en) * | 2019-05-21 | 2022-03-30 | Bristol-Myers Squibb Company | Immunomodulators |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
WO2021025031A1 (ja) | 2019-08-05 | 2021-02-11 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
BR112022004316A2 (pt) | 2019-09-22 | 2022-06-21 | Bristol Myers Squibb Co | Caracterização espacial quantitativa para terapia de antagonista lag-3 |
AU2020357502A1 (en) | 2019-09-30 | 2022-05-19 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
EP4054723A1 (en) | 2019-11-08 | 2022-09-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
EP4069729A1 (en) | 2019-12-06 | 2022-10-12 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
EP4134134A4 (en) | 2020-04-10 | 2023-12-27 | ONO Pharmaceutical Co., Ltd. | STING AGONIST COMPOUND |
CN113754736A (zh) * | 2020-06-02 | 2021-12-07 | 南京礼威生物医药有限公司 | 含酰肼结构的pd-l1环肽抑制剂 |
AU2021331476A1 (en) | 2020-08-28 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
MX2023002326A (es) | 2020-08-31 | 2023-03-21 | Bristol Myers Squibb Co | Firma de localizacion celular e inmunoterapia. |
WO2022066635A1 (en) | 2020-09-22 | 2022-03-31 | Avidea Technologies, Inc. | Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ |
AU2021364837A1 (en) | 2020-10-23 | 2023-05-25 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
CN117858719A (zh) | 2021-03-29 | 2024-04-09 | 朱诺治疗学股份有限公司 | 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法 |
KR20240006683A (ko) | 2021-05-13 | 2024-01-15 | 길리애드 사이언시즈, 인코포레이티드 | TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물 |
TW202317200A (zh) | 2021-06-11 | 2023-05-01 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗體藥物接合物之組合 |
EP4351564A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
IL314050A (en) | 2022-01-26 | 2024-09-01 | Bristol Myers Squibb Co | Combined treatment method for hepatocellular carcinoma |
WO2023196964A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine learning identification, classification, and quantification of tertiary lymphoid structures |
WO2024137776A1 (en) | 2022-12-21 | 2024-06-27 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
EP3012265B1 (en) | 2007-03-26 | 2017-06-28 | The University of Tokyo | Process for synthesizing cyclic peptide compound |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
EP2662383A1 (en) | 2008-08-25 | 2013-11-13 | Amplimmune, Inc. | PD-I antagonists and methods for treating infectious disease |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
JP5818237B2 (ja) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | N−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
WO2012074130A1 (ja) | 2010-12-03 | 2012-06-07 | 国立大学法人東京大学 | ペプチドライブラリーの製造方法、ペプチドライブラリー、及びスクリーニング方法 |
EP2717895A1 (en) | 2011-06-08 | 2014-04-16 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
WO2013132317A1 (en) * | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
KR20140142736A (ko) | 2012-03-29 | 2014-12-12 | 오리진 디스커버리 테크놀로지스 리미티드 | 인간의 pd1의 bc 루프로부터의 면역조절 사이클릭 화합물 |
JP2013253842A (ja) | 2012-06-06 | 2013-12-19 | Univ Of Tokyo | pH依存的に標的分子に結合するペプチドのスクリーニング方法 |
WO2013182240A1 (en) | 2012-06-06 | 2013-12-12 | Polyphor Ag | Beta-hairpin peptidomimetics |
AU2013273481B2 (en) * | 2012-06-06 | 2018-04-05 | Bionor Immuno As | HIV vaccine |
KR102158924B1 (ko) | 2013-03-15 | 2020-09-22 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
US9308236B2 (en) * | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
DK3041468T3 (en) | 2013-09-06 | 2018-08-13 | Aurigene Discovery Tech Ltd | CYCLIC PEPTIDOMIMETIC COMPOUNDS AS IMMUNOMODULATORS |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
MX2017003201A (es) | 2014-09-11 | 2017-05-23 | Bristol Myers Squibb Co | Inhibidores macrociclicos de las interacciones proteina/proteina de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1. |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
US10358463B2 (en) * | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
-
2015
- 2015-12-14 US US14/967,960 patent/US9861680B2/en active Active
- 2015-12-15 BR BR112017012679A patent/BR112017012679A2/pt not_active Application Discontinuation
- 2015-12-15 JP JP2017532682A patent/JP6625129B2/ja active Active
- 2015-12-15 ES ES15820747T patent/ES2940632T3/es active Active
- 2015-12-15 KR KR1020177019417A patent/KR102602643B1/ko active IP Right Grant
- 2015-12-15 EP EP15820747.2A patent/EP3233888B1/en active Active
- 2015-12-15 WO PCT/US2015/065723 patent/WO2016100285A1/en active Application Filing
- 2015-12-15 CN CN201580069483.3A patent/CN107108697B/zh active Active
- 2015-12-15 EA EA201791231A patent/EA033894B1/ru not_active IP Right Cessation
- 2015-12-15 SG SG11201704823TA patent/SG11201704823TA/en unknown
- 2015-12-15 MX MX2017007677A patent/MX2017007677A/es unknown
- 2015-12-15 CA CA2971189A patent/CA2971189A1/en not_active Abandoned
- 2015-12-15 AU AU2015362703A patent/AU2015362703A1/en not_active Abandoned
- 2015-12-17 AR ARP150104168A patent/AR103093A1/es unknown
- 2015-12-17 TW TW104142534A patent/TW201629086A/zh unknown
-
2017
- 2017-06-12 IL IL252853A patent/IL252853A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20170087518A (ko) | 2017-07-28 |
US20160175386A1 (en) | 2016-06-23 |
JP2018504379A (ja) | 2018-02-15 |
EA201791231A1 (ru) | 2018-01-31 |
JP6625129B2 (ja) | 2019-12-25 |
WO2016100285A1 (en) | 2016-06-23 |
CA2971189A1 (en) | 2016-06-23 |
IL252853A0 (en) | 2017-08-31 |
MX2017007677A (es) | 2017-10-27 |
CN107108697B (zh) | 2022-01-04 |
CN107108697A (zh) | 2017-08-29 |
EA033894B1 (ru) | 2019-12-06 |
EP3233888B1 (en) | 2023-02-22 |
SG11201704823TA (en) | 2017-07-28 |
BR112017012679A2 (pt) | 2018-03-06 |
KR102602643B1 (ko) | 2023-11-16 |
AU2015362703A1 (en) | 2017-08-03 |
US9861680B2 (en) | 2018-01-09 |
ES2940632T3 (es) | 2023-05-10 |
TW201629086A (zh) | 2016-08-16 |
EP3233888A1 (en) | 2017-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR103093A1 (es) | Péptidos macrocíclicos que inhiben interacciones proteína / proteína de proteína de la muerte (pd-1 / pd-l1) e inhiben interacción cd80 / pd-l1 | |
AR103182A1 (es) | Inmunomoduladores | |
AR107802A1 (es) | Inmunomoduladores | |
AR103969A1 (es) | Inmunomoduladores | |
AR108186A1 (es) | Péptidos macrocíclicos que inhiben las interacciones proteína / proteína, proteína de muerte programada 1 (pd-1) / ligando de pd-1 (pd-l1) y pd-l1 / cd80 | |
AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
AR091424A1 (es) | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) | |
AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
AR089489A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
AR088760A1 (es) | Derivados de pirrolopirimidina y purina | |
AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
PE20151671A1 (es) | Inhibidores macrociclicos de las interacciones proteina/proteina de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y cumulo de diferenciacion 80 (b7-1) cd80 (b7-1)/ligando de muerte programada 1 (pd-l1) | |
AR092742A1 (es) | Piridinonas antifibroticas | |
AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
AR088293A1 (es) | Inhibidores de proteina cinasa | |
AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
ECSP16074478A (es) | Compuestos novedosos | |
AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
AR104856A1 (es) | Derivados de difluorocetamida | |
AR092347A1 (es) | Derivados de azaindol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |